Entries Are Sought for Kushner Writing Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

BETHESDA, Md--The American Medical Writers Association is seeking applications for the 1996 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer.

BETHESDA, Md--The American Medical Writers Association is seekingapplications for the 1996 Rose Kushner Awards for Writing Achievementin the Field of Breast Cancer.

Categories include articles (newspapers and magazines, or scientificjournals), books (medical and lay), brochures and monographs,and scripts for video, film, or radio (medical and lay audi-ences).The winning entry in each category is awarded $1,000, providedthrough a grant from Zeneca Pharmaceuticals.

Entries must be received by May 10, 1996. For information, writeto the Rose Kushner Award Committee, American Medical WritersAssociation, 9650 Rockville Pike, Bethesda, MD 20814-3998. Phone301-493-0003 or fax 301-493-6384.

Articles in this issue
Earlier Unrelated BMT Is Effective in CML Subgroup
Taxol/Cisplatin Extends Survival in Advanced Ovarian Ca
Prostate Cancer Patients Face a Host of Psychosocial Issues
NSABP to Study Docetaxel in Operable Breast Cancer
Panel Recommends Approval of Talc for Malignant Pleural Effusions
ODAC Recommends Approval of Verluma for Staging of SCLC
Minorities Lack Internet Access to Cancer Research Data
Fludarabine Produces CRs as First-Line CLL Therapy
M.D. Anderson's C. Stratton Hill Receives Award From American Cancer Society
Managed Care: The View From Salick Managed Care
Selling 'High Risk' Part of an Oncology Practice Can Increase Financial Stability
Entries Are Sought for Kushner Writing Award
Docetaxel Effective as First-Line Breast Cancer Therapy
Roswell Park Institute Establishes Hepatic Cryosurgery Center
High-Dose RAIT May Improve Prognosis in Relapsed NHL Patients
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
July 29th 2025
Article

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

Ariana Pelosci
July 20th 2025
Article

Updated POSITIVE trial findings showed no significant breast cancer events in patients who breastfed following endocrine therapy for HR+ breast cancer.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.